Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors.

Diaz-Padilla I, Hirte H, Oza AM, Clarke BA, Cohen B, Reedjik M, Zhang T, Kamel-Reid S, Ivy SP, Hotte SJ, Razak AA, Chen EX, Brana I, Wizemann M, Wang L, Siu LL, Bedard PL.

Invest New Drugs. 2013 Oct;31(5):1182-91. doi: 10.1007/s10637-013-0001-5.

2.

A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575).

Richter S, Bedard PL, Chen EX, Clarke BA, Tran B, Hotte SJ, Stathis A, Hirte HW, Razak AR, Reedijk M, Chen Z, Cohen B, Zhang WJ, Wang L, Ivy SP, Moore MJ, Oza AM, Siu LL, McWhirter E.

Invest New Drugs. 2014 Apr;32(2):243-9. doi: 10.1007/s10637-013-9965-4.

3.

Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors.

Tolcher AW, Messersmith WA, Mikulski SM, Papadopoulos KP, Kwak EL, Gibbon DG, Patnaik A, Falchook GS, Dasari A, Shapiro GI, Boylan JF, Xu ZX, Wang K, Koehler A, Song J, Middleton SA, Deutsch J, Demario M, Kurzrock R, Wheler JJ.

J Clin Oncol. 2012 Jul 1;30(19):2348-53. doi: 10.1200/JCO.2011.36.8282.

PMID:
22529266
4.

A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors.

LoConte NK, Razak AR, Ivy P, Tevaarwerk A, Leverence R, Kolesar J, Siu L, Lubner SJ, Mulkerin DL, Schelman WR, Deming DA, Holen KD, Carmichael L, Eickhoff J, Liu G.

Invest New Drugs. 2015 Feb;33(1):169-76. doi: 10.1007/s10637-014-0166-6.

5.

A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503).

Sahebjam S, Bedard PL, Castonguay V, Chen Z, Reedijk M, Liu G, Cohen B, Zhang WJ, Clarke B, Zhang T, Kamel-Reid S, Chen H, Ivy SP, Razak AR, Oza AM, Chen EX, Hirte HW, McGarrity A, Wang L, Siu LL, Hotte SJ.

Br J Cancer. 2013 Aug 20;109(4):943-9. doi: 10.1038/bjc.2013.380.

6.

Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma.

Fishman MN, Srinivas S, Hauke RJ, Amato RJ, Esteves B, Cotreau MM, Strahs AL, Slichenmyer WJ, Bhargava P, Kabbinavar FF.

Eur J Cancer. 2013 Sep;49(13):2841-50. doi: 10.1016/j.ejca.2013.04.019.

7.

Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer.

Naing A, Kurzrock R, Burger A, Gupta S, Lei X, Busaidy N, Hong D, Chen HX, Doyle LA, Heilbrun LK, Rohren E, Ng C, Chandhasin C, LoRusso P.

Clin Cancer Res. 2011 Sep 15;17(18):6052-60. doi: 10.1158/1078-0432.CCR-10-2979.

8.

Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors.

Spunt SL, Grupp SA, Vik TA, Santana VM, Greenblatt DJ, Clancy J, Berkenblit A, Krygowski M, Ananthakrishnan R, Boni JP, Gilbertson RJ.

J Clin Oncol. 2011 Jul 20;29(21):2933-40. doi: 10.1200/JCO.2010.33.4649.

9.

Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933.

Lee SM, Moon J, Redman BG, Chidiac T, Flaherty LE, Zha Y, Othus M, Ribas A, Sondak VK, Gajewski TF, Margolin KA.

Cancer. 2015 Feb 1;121(3):432-40. doi: 10.1002/cncr.29055.

10.

Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer.

Buckner JC, Forouzesh B, Erlichman C, Hidalgo M, Boni JP, Dukart G, Berkenblit A, Rowinsky EK.

Invest New Drugs. 2010 Jun;28(3):334-42. doi: 10.1007/s10637-009-9257-1.

PMID:
19415181
11.

A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia.

Diaz-Padilla I, Wilson MK, Clarke BA, Hirte HW, Welch SA, Mackay HJ, Biagi JJ, Reedijk M, Weberpals JI, Fleming GF, Wang L, Liu G, Zhou C, Blattler C, Ivy SP, Oza AM.

Gynecol Oncol. 2015 May;137(2):216-22. doi: 10.1016/j.ygyno.2015.03.005.

PMID:
25769658
12.

Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors.

Bryce AH, Rao R, Sarkaria J, Reid JM, Qi Y, Qin R, James CD, Jenkins RB, Boni J, Erlichman C, Haluska P.

Invest New Drugs. 2012 Oct;30(5):1934-41. doi: 10.1007/s10637-011-9742-1.

13.

A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041).

Chiu JW, Hotte SJ, Kollmannsberger CK, Renouf DJ, Cescon DW, Hedley D, Chow S, Moscow J, Chen Z, Perry M, Diaz-Padilla I, Tan D, Hirte H, McWhirter E, Chen H, Siu LL, Bedard PL.

Invest New Drugs. 2016 Feb;34(1):104-11. doi: 10.1007/s10637-015-0313-8.

15.

Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers.

Khawaja MR, Nick AM, Madhusudanannair V, Fu S, Hong D, McQuinn LM, Ng CS, Piha-Paul SA, Janku F, Subbiah V, Tsimberidou A, Karp D, Meric-Bernstam F, Lu KH, Naing A.

Cancer Chemother Pharmacol. 2016 May;77(5):973-7. doi: 10.1007/s00280-016-3009-7.

PMID:
27014780
16.

A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma.

De Jesus-Acosta A, Laheru D, Maitra A, Arcaroli J, Rudek MA, Dasari A, Blatchford PJ, Quackenbush K, Messersmith W.

Invest New Drugs. 2014 Aug;32(4):739-45. doi: 10.1007/s10637-014-0083-8.

17.

Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies.

Deenen MJ, Klümpen HJ, Richel DJ, Sparidans RW, Weterman MJ, Beijnen JH, Schellens JH, Wilmink JW.

Invest New Drugs. 2012 Aug;30(4):1557-65. doi: 10.1007/s10637-011-9723-4.

18.

Inhibition of the NOTCH pathway using γ-secretase inhibitor RO4929097 has limited antitumor activity in established glial tumors.

Dantas-Barbosa C, Bergthold G, Daudigeos-Dubus E, Blockus H, Boylan JF, Ferreira C, Puget S, Abely M, Vassal G, Grill J, Geoerger B.

Anticancer Drugs. 2015 Mar;26(3):272-83. doi: 10.1097/CAD.0000000000000190.

PMID:
25486598
19.

A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.

Hidalgo M, Buckner JC, Erlichman C, Pollack MS, Boni JP, Dukart G, Marshall B, Speicher L, Moore L, Rowinsky EK.

Clin Cancer Res. 2006 Oct 1;12(19):5755-63.

20.

A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors.

Fujisaka Y, Yamada Y, Yamamoto N, Horiike A, Tamura T.

Jpn J Clin Oncol. 2010 Aug;40(8):732-8. doi: 10.1093/jjco/hyq047.

PMID:
20430774

Supplemental Content

Support Center